S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
Log in
NASDAQ:INMB

INmune Bio Stock Forecast, Price & News

$13.12
-1.19 (-8.32 %)
(As of 03/8/2021 05:20 PM ET)
Add
Compare
Today's Range
$13.00
Now: $13.12▼
$14.92
50-Day Range
$15.37
MA: $20.01▼
$26.85
52-Week Range
$2.20
Now: $13.12▼
$29.99
Volume193,674 shs
Average Volume388,208 shs
Market Capitalization$176.44 million
P/E RatioN/A
Dividend YieldN/A
Beta3.01
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; and LivNate to treat patients with non-alcoholic steatohepatitis. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was founded in 2015 and is headquartered in La Jolla, California.
INmune Bio logo

Headlines

INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021
March 8, 2021 |  finance.yahoo.com
INmune Bio, Inc. Announces Fourth Quarter and Full Year 2020 Results and Provides Business Update
March 4, 2021 |  finance.yahoo.com
INmune Bio, Inc. to Host Earnings Call
March 4, 2021 |  finance.yahoo.com
INmune Bio, Inc. to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on Thursday, March 4
February 25, 2021 |  finance.yahoo.com
We Think INmune Bio (NASDAQ:INMB) Can Easily Afford To Drive Business Growth
January 25, 2021 |  finance.yahoo.com
Why INmune Bio Stock Soared Then Sank Today
January 23, 2021 |  finance.yahoo.com
INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer’s Disease in Phase 1b Trial
January 21, 2021 |  finance.yahoo.com
INmune Bio, Inc. to Host Key Opinion Leader Webinar on Thursday, January 21 at 8 AM ET
January 13, 2021 |  finance.yahoo.com
Do Hedge Funds Love Inmune Bio Inc. (INMB)?
November 27, 2020 |  finance.yahoo.com
Bexion Pharmaceuticals Announces the Addition of Dr. Raymond J. Tesi to Board of Directors
November 17, 2020 |  finance.yahoo.com
INmune Bio, Inc. (INMB) CEO RJ Tesi on Q3 2020 Results - Earnings Call Transcript
November 8, 2020 |  seekingalpha.com
INmune Bio EPS misses by $0.19
November 5, 2020 |  seekingalpha.com
INmune Bio, Inc. Announces Third Quarter Results and Provides Business Update
November 5, 2020 |  finance.yahoo.com
INmune Bio, Inc. to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on Thursday, November 5
October 29, 2020 |  finance.yahoo.com
Do Insiders Own Lots Of Shares In INmune Bio, Inc. (NASDAQ:INMB)?
October 26, 2020 |  finance.yahoo.com
INmune Bio to present preliminary phase I data on Alzheimer’s drug discovery
October 5, 2020 |  seekingalpha.com
INmune Bio to present interim data from early-stage Alzheimer’s study
October 5, 2020 |  seekingalpha.com
INmune Bio, Inc. to Host Key Opinion Leader Webinar on Treatment Resistant Depression on Tuesday, September 29
September 23, 2020 |  finance.yahoo.com
INmune Bio secures $2.9M funding to advance a mid-stage depression study with lead drug
September 16, 2020 |  seekingalpha.com
INmune Bio, Inc. Awarded $2.9 Million NIH Small Business Innovation Research Grant to Support Phase 2 Study of XPro1595 in Patients with Treatment Resistant Depression
September 16, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INMB
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.inmunebio.com
Phone858-964-3720
Employees4
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio17.73
Quick Ratio17.73

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.19 per share
Price / Book5.99

Profitability

EPS (Most Recent Fiscal Year)($0.75)
Net Income$-7,680,000.00
Net MarginsN/A
Return on Equity-41.18%
Return on Assets-39.34%

Miscellaneous

Outstanding Shares13,448,000
Market Cap$176.44 million
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable

MarketRank™

Overall MarketRank™

1.53 out of 5 stars

Medical Sector

448th out of 1,971 stocks

Biological Products, Except Diagnostic Industry

61st out of 177 stocks

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$13.12
-1.19 (-8.32 %)
(As of 03/8/2021 05:20 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INMB News and Ratings via Email

Sign-up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











INmune Bio (NASDAQ:INMB) Frequently Asked Questions

Is INmune Bio a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for INmune Bio in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INmune Bio stock.
View analyst ratings for INmune Bio or view top-rated stocks.

What stocks does MarketBeat like better than INmune Bio?

Wall Street analysts have given INmune Bio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but INmune Bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is INmune Bio's next earnings date?

INmune Bio is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for INmune Bio.

How were INmune Bio's earnings last quarter?

INmune Bio, Inc. (NASDAQ:INMB) issued its earnings results on Wednesday, March, 3rd. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.31) by $0.05. The business earned $0.01 million during the quarter.
View INmune Bio's earnings history.

How has INmune Bio's stock been impacted by COVID-19 (Coronavirus)?

INmune Bio's stock was trading at $4.80 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, INMB shares have increased by 171.0% and is now trading at $13.01.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for INMB?

4 analysts have issued 1-year price objectives for INmune Bio's shares. Their forecasts range from $13.00 to $26.00. On average, they expect INmune Bio's stock price to reach $19.25 in the next twelve months. This suggests a possible upside of 48.0% from the stock's current price.
View analysts' price targets for INmune Bio or view top-rated stocks among Wall Street analysts.

Who are INmune Bio's key executives?

INmune Bio's management team includes the following people:
  • Dr. Raymond Joseph Tesi, Co-Founder, Pres, CEO, Chief Medical Officer & Chairman (Age 65, Pay $247.5k)
  • Mr. David J. Moss M.B.A., CFO, Treasurer & Sec. (Age 51, Pay $247.5k)
  • Dr. Mark William Lowdell BSc, MSc, Ph.D., FRCPath, MICR, Chief Scientific Officer & Chief Manufacturing Officer (Age 58, Pay $142.81k)
  • Mr. Joshua S. Schoonover Esq., Assoc. Gen. Counsel
  • Dr. Christopher J. Barnum, Director of Neuroscience

Who are some of INmune Bio's key competitors?

Some companies that are related to INmune Bio include Vaxart (VXRT), Orchard Therapeutics (ORTX), Osiris Therapeutics (OSIR), Tarsus Pharmaceuticals (TARS), Athira Pharma (ATHA), Agenus (AGEN), Precision BioSciences (DTIL), DBV Technologies (DBVT), Jounce Therapeutics (JNCE), Solid Biosciences (SLDB), Compugen (CGEN), MeiraGTx (MGTX), Curis (CRIS), Oyster Point Pharma (OYST) and Poseida Therapeutics (PSTX).
View all of INMB's competitors.

What other stocks do shareholders of INmune Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other INmune Bio investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Cidara Therapeutics (CDTX), Gilead Sciences (GILD), Cisco Systems (CSCO), Vaxart (VXRT), Micron Technology (MU), Novavax (NVAX) and SCYNEXIS (SCYX).

What is INmune Bio's stock symbol?

INmune Bio trades on the NASDAQ under the ticker symbol "INMB."

Who are INmune Bio's major shareholders?

INmune Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Ikarian Capital LLC (1.62%), BlackRock Inc. (0.16%), Diametric Capital LP (0.09%), Northern Trust Corp (0.09%), Dimensional Fund Advisors LP (0.08%) and Dimensional Fund Advisors LP (0.08%). Company insiders that own INmune Bio stock include David J Moss, Linda F Powers, Mark William Lowdell, Raymond Joseph Tesi and Scott Juda.
View institutional ownership trends for INmune Bio.

Which institutional investors are selling INmune Bio stock?

INMB stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, and Dimensional Fund Advisors LP.
View insider buying and selling activity for INmune Bio or view top insider-selling stocks.

Which institutional investors are buying INmune Bio stock?

INMB stock was bought by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Diametric Capital LP, Northern Trust Corp, BlackRock Inc., Capital Asset Advisory Services LLC, and FNY Investment Advisers LLC. Company insiders that have bought INmune Bio stock in the last two years include David J Moss, Linda F Powers, Mark William Lowdell, Raymond Joseph Tesi, and Scott Juda.
View insider buying and selling activity for INmune Bio or or view top insider-buying stocks.

How do I buy shares of INmune Bio?

Shares of INMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is INmune Bio's stock price today?

One share of INMB stock can currently be purchased for approximately $13.01.

How much money does INmune Bio make?

INmune Bio has a market capitalization of $174.96 million. The company earns $-7,680,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

How many employees does INmune Bio have?

INmune Bio employs 4 workers across the globe.

What is INmune Bio's official website?

The official website for INmune Bio is www.inmunebio.com.

Where are INmune Bio's headquarters?

INmune Bio is headquartered at 1200 PROSPECT STREET SUITE 525, LA JOLLA CA, 92037.

How can I contact INmune Bio?

INmune Bio's mailing address is 1200 PROSPECT STREET SUITE 525, LA JOLLA CA, 92037. The company can be reached via phone at 858-964-3720 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.